These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22530017)

  • 1. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
    Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
    Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T2 relaxation time in patients with Parkinson's disease.
    Antonini A; Leenders KL; Meier D; Oertel WH; Boesiger P; Anliker M
    Neurology; 1993 Apr; 43(4):697-700. PubMed ID: 8469325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical MRI for iron detection in Parkinson's disease.
    Rossi M; Ruottinen H; Soimakallio S; Elovaara I; Dastidar P
    Clin Imaging; 2013; 37(4):631-6. PubMed ID: 23522789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis.
    Jesse S; Kassubek J; Müller HP; Ludolph AC; Unrath A
    BMC Neurol; 2012 Dec; 12():163. PubMed ID: 23273141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.
    Wu SF; Zhu ZF; Kong Y; Zhang HP; Zhou GQ; Jiang QT; Meng XP
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2605-8. PubMed ID: 25317792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
    Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
    Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
    Kim TH; Lee JH
    PLoS One; 2014; 9(11):e112512. PubMed ID: 25386854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Application of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Techniques to Investigate the Effect of Iron Deposition on Microstructural Changes in the Brain in Parkinson's Disease.
    Yang L; Cheng Y; Sun Y; Xuan Y; Niu J; Guan J; Rong Y; Jia Y; Zhuang Z; Yan G; Wu R
    Front Aging Neurosci; 2022; 14():792778. PubMed ID: 35370619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex.
    Sastry S; Arendash GW
    Neuroscience; 1995 Aug; 67(3):649-66. PubMed ID: 7545796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
    O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
    Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.